Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Turns To Plegridy As Avonex Sales Wane

This article was originally published in The Pink Sheet Daily

Executive Summary

The MS powerhouse got approval for its fourth treatment for the disease; the drug will help bolster the franchise while sales of some of the other drugs are eroded.

You may also be interested in...

Biogen Leans On Plegridy To Help Extend The Life Of Avonex

The drug maker reports positive late-stage data for its newest multiple sclerosis product. The pegylated interferon could help its existing injectable interferon franchise maintain share against new oral options.

Biogen/Elan Seek First-Line Claim For Tysabri In JCV-Negative MS Patients

Given the risks of progressive multifocal leukoencephalopathy, a proposed restriction appears aimed at blunting the potentially unfavorable impact that longer duration of use in the first-line setting would have on natalizumab’s risk/benefit profile.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts